Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2018
Pharmacy Choice - Pharmacy News - November 19, 2018

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
11/19/18 - FDA Approves AEMCOLOâ?¢ (Rifamycin), the First Antibiotic Approved for the Treatment of Travelersâ?? Diarrhea in Over a Decade
Dublin, Ireland- November 19, 2018- Cosmo Pharmaceuticals N.V. announced that the U.S. Food and Drug Administration has approved AEMCOLOâ?¢, containing 194 mg of Rifamycin as delayed-release tablets, a new minimally-absorbed antibiotic that is delivered to the colon, for treatment of Travelers' Diarrhea caused by non-invasive strains of Escherichia
11/19/18 - FDA approves antibacterial drug to treat travelers` diarrhea [Tehran Times (Iran)]
"Travelers` diarrhea affects millions of people each year and having treatment options for this condition can help reduce symptoms of the condition," said Edward Cox, M.D., M.P.H., director of the Office of Antimicrobial Products in the FDA`s Center for Drug Evaluation and Research. The highest-risk destinations are in most of Asia as well as the M
11/19/18 - FDA Approves New Drug to Treat Travelers Diarrhea [Syrian Arab News Agency]
"Travelers` diarrhea affects millions of people each year and having treatment options for this condition can help reduce symptoms of the condition," said Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in the FDAs Center for Drug Evaluation and Research. The highest-risk destinations are in most of Asia as well as the Middle
11/19/18 - FDA approves treatment for peripheral T-cell lymphoma
The US Food and Drug Administration has approved first-line treatment for newly diagnosed peripheral T-cell lymphoma using a new review program... The post FDA approves treatment for peripheral T-cell lymphoma appeared first on European Pharmaceutical Review.
11/19/18 - Gilead Sciences: China NMPA Approves Vemlidy For Chronic HBV Infection
FOSTER CITY- Gilead Sciences, Inc. announced that the China National Medical Products Administration has approved Vemlidy 25 mg, for chronic hepatitis B Virus Infection in adults and adolescents. Jinlin Hou, Nanfang Hospital of Southern Medical University. Vemlidy received marketing approval from the U.S. Food and Drug Administration and the Japane
11/19/18 - Travel Diarrhea Medicine Rifamycin Approved by FDA [Tehran Times (Iran)]
"Travelers` diarrhea affects millions of people each year and having treatment options for this condition can help reduce symptoms of the condition," said Edward Cox, M.D., M.P.H., director of the Office of Antimicrobial Products in the FDAs Center for Drug Evaluation and Research. The highest-risk destinations are located in Asia as well as the Mi

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415